3rd Cell and Gene Therapy Pricing and Reimbursement Summit

Memo

The cell and gene therapy sector is accelerating faster than the systems designed to pay for it. With 39 FDA approved CGTs and more than 80 expected by 2032, the widening gap between scientific progress and pricing, policy, and reimbursement frameworks is threatening real world patient access. At the same time, the last year has brought major changes, from the Cell and Gene Therapy Access Model and outcomes based agreements to rising concerns about coverage and the policy changes still to come. Returning to Washington DC, the 3rd Cell and Gene Therapy Pricing and Reimbursement Summit is the only meeting built specifically for cell and gene therapy biopharma, commercial and government payers, policymakers, and healthcare providers to confront these challenges head on. Through exclusive case studies from newly commercialized companies, deep dives into the latest policy shifts, and practical frameworks for value communication, you’ll gain the insights needed to navigate the current commercialization landscape and be part of the conversation discussing what policy changes will be needed next. Join the stakeholders defining the future of cell and gene therapy affordability, and leave with the strategies to secure coverage, expand treatment capacity, and unlock patient access in 2026 and beyond. URLs:Tickets: https://go.evvnt.com/3561414-2?pid=5569Brochure: https://go.evvnt.com/3561414-3?pid=5569 Date and Time: On Tue, 14 Jul 2026 08:00 - Thu, 16 Jul 2026 16:00 Venue Details: Le Meridien Washington, D.C., The Madison, 1177 15th Street Northwest, Washington, District of Columbia, 20005, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Regulatory Affairs Prices:Drug Developer Pricing - Conference + 2 Workshops: USD 4397.00,Drug Developer Pricing - Conference + 1 Workshops: USD 3748.00,Drug Developer Pricing - Conference Only: USD 3099.00,Academic and Research Institutes - Conference + 2 Workshops: USD 3797.00,Academic and Research Institutes - Conference + 1 Workshops: USD 3248.00,Academic and Research Institutes - Conference Only: USD 2699.00,Solution and Service Providers - Conference + 2 Workshops: USD 5297.00,Solution and Service Providers - Conference + 1 Workshops: USD 4548.00,Solution and Service Providers - Conference Only: USD 3799.00 Speakers: Jon Weber, Senior Director Cell and Gene Therapy Market Access Lead, Bayer, Jamie Gibfried, Senior Director US Cell Therapy Access Strategy, Bristol Myers Squibb, Jillian Fahey, Executive Director Cell Therapy Patient Access and Field Reimbursement, Bristol Myers Squibb, Arielle Gurwitch, Senior Director US Public Policy, Eli Lilly, Laura Okpala, Executive Director and Head of Reimbursement Policy and Government Affairs, Gilead Sciences, Vadi Shahid, Director Payment and Health Care Delivery Policy, Johnson and Johnson, Brad Berigan, Senior Director and Head of Market Access Strategic Account Engagement, Kite Pharma, Mark Prygoda, Senior Director US Market Access Strategy and Operations, Autolus, Ravi Singh, Vice President Market Access, Advocacy and Policy, Genetix Biotherapeutics, Jodie Wehling, Vice President Market Access and Head of Market Access, Trade and Distribution, Mesoblast, Carrie Edwards, Wolkoff Director, Government Account, MACs, MCD, VA/ DOD, Neurotech Pharmaceuticals, Kimberly Burlison, Head US Market Access, Orchard Therapeutics, David Davenport, Director US Policy, Alliance for Regenerative Medicine, Marianne Hamilton Lopez, Senior Research Director Biomedical Innovation, Duke-Margolis Center for Health Policy, Taylor Hittle, Executive Director, Partnership for Employer-Sponsored Coverage, Mark Trusheim, Senior Strategy Advisor NEWDIGS, Tufts Medical Center, Paul Eiting, Managing Director Legislative and Regulatory Policy, Blue Cross Blue Shield Association, Eugean Jiwanmall, Lead Research Analyst for Medical Policy and Health Technology Evaluation, Independence Blue Cross Family of Companies and Independence Health Group, Terry Cothran, Chief Pharmacy Officer, Oklahoma Health Care Authority, Michael Byrne, Medical Director Cellular Therapy, OneOncology, Chad Bissell, Vice President Drug Launch Services and Clinical Operations, Artia Solutions - Powered by Petauri